Novartis and Alexion lead protests at NICE proposals

17 March 2017

The controllers of the purse strings for the National Health Service (NHS) for England made a statement on Wednesday that they are unwilling to continue to pay for patients to access innovative treatments for rare diseases to the extent that they do now.

This came with the announcement of the proposals from cost-effectiveness watchdog National Institute for Health and Clinical Excellence (NICE) and NHS England for a dynamic upper-limit for costs per quality adjusted life year (QALY) above which they will not recommend funding for highly specialized technologies (HST) treatments.

"This decision will have a great impact on many patients, from people with heart disease and diabetes to those with cancer, who are in great need of new treatments"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK